India Branded Generics Market Size & Outlook, 2021-2030
India branded generics market, 2018-2030 (US$M)
Related Markets
India branded generics market highlights
- The India branded generics market generated a revenue of USD 22.7 billion in 2021 and is expected to reach USD 41.9 billion by 2030.
- The India market is expected to grow at a CAGR of 7% from 2022 to 2030.
- In terms of segment, anti-hypertensive was the largest revenue generating drug class in 2021.
- Anti-hypertensive is the most lucrative drug class segment registering the fastest growth during the forecast period.
Branded generics market data book summary
| Market revenue in 2021 | USD 22.7 billion |
| Market revenue in 2030 | USD 41.9 billion |
| Growth rate | 7% (CAGR from 2021 to 2030) |
| Largest segment | Anti-hypertensive |
| Fastest growing segment | Anti-hypertensive |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD billion |
| Market segmentation | Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics |
| Key market players worldwide | Teva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc |
Other key industry trends
- In terms of revenue, India accounted for 9.9% of the global branded generics market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China branded generics market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 41.9 billion by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Branded Generics Market Scope
Branded Generics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
India branded generics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.
Anti-hypertensive was the largest segment with a revenue share of 15.86% in 2021. Horizon Databook has segmented the India branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
Indian branded generics market is anticipated to witness significant market growth over the coming years. Government initiatives such as Pradhan Mantri Bhartiya Janaushadhi Pariyojana, Ayushman Bharat, and PMNRF may improve public access to treatments, encouraging generic players.
Unbranded generics in India are associated with various misconceptions, including distrust of product quality and effectiveness. Owing to this, there is an opportunity for branded generics players to strengthen their market share in the Indian market.
In addition, physicians are not bonded with any law for prescribing medicine in India. The increasing burden of chronic diseases and growing geriatric population are also expected to contribute to growth of branded generics market in the country.
Reasons to subscribe to India branded generics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of India branded generics market databook
-
Our clientele includes a mix of branded generics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India branded generics market , including forecasts for subscribers. This country databook contains high-level insights into India branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
India branded generics market size, by drug class, 2018-2030 (US$M)
India Branded Generics Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
